Literature DB >> 31502173

Bioinformatics Tools and Resources for Cancer Immunotherapy Study.

Alida Palmisano1, Julia Krushkal1, Ming-Chung Li1, Jianwen Fang1, Dmitriy Sonkin1, George Wright1, Laura Yee1, Yingdong Zhao2, Lisa McShane3.   

Abstract

In recent years, cancer immunotherapy has emerged as a highly promising approach to treat patients with cancer, as the patient's own immune system is harnessed to attack cancer cells. However, the application of these approaches is still limited to a minority of patients with cancer and it is difficult to predict which patients will derive the greatest clinical benefit.One of the challenges faced by the biomedical community in the search of more effective biomarkers is the fact that translational research efforts involve collecting and accessing data at many different levels: from the type of material examined (e.g., cell line, animal models, clinical samples) to multiple data type (e.g., pharmacodynamic markers, genetic sequencing data) to the scale of a study (e.g., small preclinical study, moderate retrospective study on stored specimen sets, clinical trials with large cohorts).This chapter reviews several publicly available bioinformatics tools and data resources for high throughput molecular analyses applied to a range of data types, including those generated from microarray, whole-exome sequencing (WES), RNA-seq, DNA copy number, and DNA methylation assays, that are extensively used for integrative multidimensional data analysis and visualization.

Entities:  

Keywords:  Bioinformatics tools; DNA copy number; DNA methylation; RNA-seq; Whole-exome sequencing (WES)

Mesh:

Substances:

Year:  2020        PMID: 31502173     DOI: 10.1007/978-1-4939-9773-2_29

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  1 in total

Review 1.  The Importance of STK11/LKB1 Assessment in Non-Small Cell Lung Carcinomas.

Authors:  Baharia Mograbi; Simon Heeke; Paul Hofman
Journal:  Diagnostics (Basel)       Date:  2021-01-29
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.